Red yeast rice and olive leaf extract are both sold for “heart health,” but they answer different questions. Red yeast rice is mainly a cholesterol conversation because some products contain monacolin K, a compound structurally identical to lovastatin. Olive leaf extract is mainly supported by limited blood-pressure research in specific study populations. The better choice is therefore not “which is stronger,” but which claim matches the person’s goal, product testing, and safety situation.
A practical comparison is this: red yeast rice may affect LDL cholesterol when it contains meaningful monacolin K, but the same fact makes safety and regulation more serious. Olive leaf extract has human data for blood pressure, including one active-controlled stage-1 hypertension trial, but that trial does not prove that every olive leaf capsule lowers blood pressure or replaces treatment.
What each supplement is actually being compared for
The NCCIH red yeast rice overview explains that red yeast rice is rice fermented with Monascus and that fermentation can produce monacolins, including monacolin K. Monacolin K is structurally identical to lovastatin, which is why red yeast rice products are usually judged by LDL-lowering potential, monacolin content, citrinin testing, and statin-like risks.
Olive leaf extract is a different type of evidence. One relevant human study is an olive leaf stage-1 hypertension trial published in 2011. It studied adults with stage-1 hypertension for 8 weeks after a 4-week run-in period. The study used the named olive leaf extract EFLA 943 at 500 mg twice daily and compared it with captopril, an active blood-pressure medicine, started at 12.5 mg twice daily and titrated if needed. These are study methods, not instructions for replacing a prescription.
What the olive leaf trial actually showed
In that trial, mean systolic blood pressure started at 149.3±5.58 mmHg in the olive leaf group and 148.4±5.56 mmHg in the captopril group. After 8 weeks, mean systolic reductions were -11.5±8.5 mmHg with olive leaf extract and -13.7±7.6 mmHg with captopril. Mean diastolic reductions were -4.8±5.5 mmHg and -6.4±5.2 mmHg, respectively. The abstract says the reductions were significant from baseline and were not significantly different between groups.
That is useful, but it has limits. The study was not a general “olive leaf beats red yeast rice” test, was not a placebo-only supplement trial, and used a defined extract and dose in people with stage-1 hypertension. The reported absence of a statistically significant difference does not by itself establish universal interchangeability with captopril. Nor do these blood-pressure numbers establish outcomes for other extracts, people with normal blood pressure or a person already taking medication. The study also measured lipids and reported a triglyceride reduction in the olive leaf group, but that separate outcome does not establish a head-to-head LDL advantage over red yeast rice.
Why red yeast rice needs product testing before comparison
Red yeast rice is hard to compare by name alone because monacolin K can vary widely. A red yeast rice supplement variability study analyzed 28 U.S. retail brands in 2017. Monacolin K was not detected in two brands. In the 26 brands that contained it, the amount ranged from 0.09 to 5.48 mg per 1,200 mg of red yeast rice, and label-directed daily intake ranged from 0.09 to 10.94 mg.
That study was a 2017 U.S. sample, not a live measurement of every current product. Its value is the principle: a label that says “red yeast rice” or gives only capsule weight does not tell you the active monacolin exposure. A current batch certificate of analysis (COA) should state what is being measured, such as monacolin K lactone, monacolin K acid, total monacolin K, or total monacolins.
Safety is not solved by calling the dose “natural”
The safety discussion should not imply that a small or “natural” amount is automatically safe. A 2025 EFSA monacolins safety opinion reviewed additional data submitted during the EU scrutiny period and reiterated concern that exposure to monacolin K from red yeast rice at intake levels as low as 3 mg/day could lead to severe musculoskeletal effects, including rhabdomyolysis, and liver effects. EFSA concluded that the new data did not allow it to identify a daily intake from red yeast rice supplements that does not raise safety concerns for the general population or vulnerable subgroups.
NCCIH also notes a U.S.-specific regulatory point: red yeast rice products with enhanced or added lovastatin cannot be marketed as dietary supplements in the United States. This is a U.S. regulatory position, not a statement of the rules in every country. A laboratory report does not by itself establish that a product is legally marketed or medically suitable.
Comparing products without overlooking risk
For LDL cholesterol, red yeast rice is the more directly relevant supplement category only if a tested product contains monacolin K, but that same active compound creates statin-like safety and medication-interaction concerns. For blood-pressure support, olive leaf extract has a more relevant human trial signal, but only within the limits of the studied extract, population, and 8-week design.
There is no basis in the studies discussed here for assuming that taking the two together combines their benefits safely. Start by identifying the target marker—LDL cholesterol, blood pressure, triglycerides, or general wellness—then check the product’s current lab report and discuss medication overlap with a clinician. Without that, “red yeast rice vs olive leaf extract” is only a category comparison, not a safe personal plan.
Citrinin is a separate issue from monacolin strength: NCCIH notes that this contaminant can damage the kidneys. A low monacolin result therefore does not settle overall product safety. NCCIH also advises against red yeast rice during pregnancy or breastfeeding and notes potential statin-like drug interactions. Bring the complete ingredient list and your medication list to the discussion, rather than comparing only the headline ingredient.